INTERVENTION 1:	Intervention	0
Treatment (Ziv-afibercept)	Intervention	1
Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.	Intervention	2
hour	UO:0000032	37-41
day	UO:0000033	45-48
day	UO:0000033	76-79
disease	DOID:4,OGMS:0000031	99-106
Inclusion Criteria:	Eligibility	0
Histologically or cytologically confirmed adenocarcinoma of the breast	Eligibility	1
adenocarcinoma	DOID:299	42-56
breast	UBERON:0000310	64-70
Clinical evidence of metastatic disease	Eligibility	2
disease	DOID:4,OGMS:0000031	32-39
No more than 2 prior chemotherapy regimens for metastatic disease	Eligibility	3
disease	DOID:4,OGMS:0000031	58-65
Prior neoadjuvant or adjuvant chemotherapy allowed*	Eligibility	4
adjuvant	CHEBI:60809	9-17
adjuvant	CHEBI:60809	21-29
At least 1 prior regimen (in any setting) must have included a taxane and/or an anthracycline	Eligibility	5
taxane	CHEBI:36064	63-69
anthracycline	CHEBI:48120	80-93
Measurable disease, defined as  1 lesion whose longest diameter can be accurately measured per RECIST criteria	Eligibility	6
disease	DOID:4,OGMS:0000031	11-18
diameter	PATO:0001334	55-63
No nonmeasurable disease, defined as all other lesions, including small lesions(longest diameter < 20 mm) and truly nonmeasurable lesions, including the following:	Eligibility	7
disease	DOID:4,OGMS:0000031	17-24
diameter	PATO:0001334	88-96
Bone lesions	Eligibility	8
Leptomeningeal disease	Eligibility	9
disease	DOID:4,OGMS:0000031	15-22
Ascites	Eligibility	10
ascites	HP:0001541	0-7
Pleural/pericardial effusion	Eligibility	11
Inflammatory breast disease	Eligibility	12
breast disease	DOID:3463	13-27
Lymphangitis cutis/pulmonis	Eligibility	13
lymphangitis	DOID:9317	0-12
Abdominal masses that are not confirmed and followed by imaging techniques	Eligibility	14
Cystic lesions	Eligibility	15
Patients with HER2-positive tumors (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization [FISH]) must have received  1 prior trastuzumab (Herceptin速)-containing regimen in either the adjuvant or metastatic setting, unless there was a contraindication	Eligibility	16
immunohistochemistry	BAO:0000415	42-62
adjuvant	CHEBI:60809	207-215
contraindication	OAE:0000055	258-274
No known CNS metastases	Eligibility	17
No evidence of leptomeningeal involvement	Eligibility	18
Hormone receptor status not specified	Eligibility	19
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Male or female	Eligibility	20
male	CHEBI:30780,PATO:0000384	0-4
male	CHEBI:30780,PATO:0000384	10-14
female	PATO:0000383	8-14
Menopausal status not specified	Eligibility	21
ECOG performance status 0-1	Eligibility	22
Life expectancy > 3 months	Eligibility	23
WBC  3,000/mm続	Eligibility	24
Absolute neutrophil count  1,500/mm続	Eligibility	25
Platelet count  75,000/mm続	Eligibility	26
platelet count	CMO:0000029	0-14
Hemoglobin > 8.0 g/dL	Eligibility	27
hemoglobin	CHEBI:35143	0-10
Bilirubin  1.5 times upper limit of normal (ULN)	Eligibility	28
Alkaline phosphatase  3 times ULN	Eligibility	29
phosphatase	GO:0016791,BAO:0000295	9-20
AST and ALT  2.5 times ULN	Eligibility	30
Creatinine  1.5 times ULN	Eligibility	31
creatinine	CHEBI:16737	0-10
Urine protein:creatinine ratio < 1 OR urine protein < 500 mg by 24-hour urine collection	Eligibility	32
urine	UBERON:0001088	0-5
urine	UBERON:0001088	38-43
urine	UBERON:0001088	72-77
protein	CHEBI:36080,BAO:0000175	6-13
protein	CHEBI:36080,BAO:0000175	44-51
creatinine	CHEBI:16737	14-24
ratio	UO:0000190	25-30
Not pregnant or nursing	Eligibility	33
Negative pregnancy test	Eligibility	34
Fertile patients must use effective contraception during and for 6 months after completion of study treatment	Eligibility	35
No significant traumatic injury within the past 4 weeks	Eligibility	36
No history of allergy or hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, drug product excipients, or agents chemically or biologically similar to VEGF Trap	Eligibility	37
history	BFO:0000182	3-10
allergy	HP:0012393	14-21
hypersensitivity	GO:0002524,DOID:1205	25-41
ovary	UBERON:0000992	61-66
drug	CHEBI:23888	120-124
product	BAO:0003067	72-79
product	BAO:0003067	125-132
No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days	Eligibility	38
abscess	HP:0025615	71-78
No nonhealing wound, fracture, or ulcer	Eligibility	39
ulcer	OAE:0004372	34-39
No stage III or IV invasive, nonbreast malignancy within the past 5 years	Eligibility	40
No history of lung carcinoma of squamous cell type	Eligibility	41
history	BFO:0000182	3-10
lung carcinoma	DOID:3905	14-28
No clinically significant cardiovascular disease, including any of the following:	Eligibility	42
disease	DOID:4,OGMS:0000031	41-48
Cerebrovascular accident or stroke within the past 6 months	Eligibility	43
stroke	HP:0001297,DOID:6713	28-34
Uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg OR systolic BP > 180 mm Hg if diastolic blood pressure < 90 mm Hg on  2 separate occasions within the past 3 months	Eligibility	44
hypertension	HP:0000822,DOID:10763	13-25
blood	UBERON:0000178	38-43
blood	UBERON:0000178	114-119
diastolic blood pressure	CMO:0000005	104-128
Myocardial infarction, coronary artery bypass graft, or unstable angina within the past 6 months	Eligibility	45
myocardial infarction	HP:0001658,DOID:5844	0-21
coronary artery	UBERON:0001621	23-38
New York Heart Association class III or IV cardiovascular disease	Eligibility	46
heart	UBERON:0000948	9-14
disease	DOID:4,OGMS:0000031	58-65
Serious cardiac arrhythmia requiring medication	Eligibility	47
arrhythmia	HP:0011675	16-26
Peripheral vascular disease  grade 2 within the past 6 months	Eligibility	48
peripheral vascular disease	DOID:341	0-27
Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months	Eligibility	49
pulmonary embolism	HP:0002204,DOID:9477	0-18
vein	UBERON:0001638	25-29
thrombosis	DOID:0060903	30-40
No evidence of bleeding diathesis or uncontrolled coagulopathy	Eligibility	50
No active, unresolved infection	Eligibility	51
active	PATO:0002354	3-9
No serious concurrent medical condition that would preclude study participation	Eligibility	52
condition	PDRO:0000129	30-39
No other condition or circumstance that would preclude compliance with study requirements	Eligibility	53
condition	PDRO:0000129	9-18
See Disease Characteristics	Eligibility	54
disease	DOID:4,OGMS:0000031	4-11
Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting allowed	Eligibility	55
adjuvant	CHEBI:60809	33-41
adjuvant	CHEBI:60809	43-51
No prior bevacizumab	Eligibility	56
More than 4 weeks since prior chemotherapy, endocrine therapy, experimental drug therapy, or immunotherapy and recovered	Eligibility	57
drug	CHEBI:23888	76-80
More than 4 weeks since prior major surgery or open biopsy	Eligibility	58
surgery	OAE:0000067	36-43
More than 7 days since prior core biopsy	Eligibility	59
More than 2 weeks since prior radiotherapy, except if to a nontarget lesion only	Eligibility	60
radiotherapy	OAE:0000235	30-42
Prior radiotherapy to a target lesion allowed only if there has been clear progression of the lesion since radiotherapy was completed	Eligibility	61
radiotherapy	OAE:0000235	6-18
radiotherapy	OAE:0000235	107-119
target	BAO:0003064	24-30
Prior single-dose palliative radiotherapy within the past 2 weeks allowed	Eligibility	62
radiotherapy	OAE:0000235	29-41
No concurrent major surgery	Eligibility	63
surgery	OAE:0000067	20-27
No concurrent trastuzumab	Eligibility	64
Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed provided the following criteria are met:	Eligibility	65
warfarin	CHEBI:10033	43-51
INR in-range (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin	Eligibility	66
stable	HP:0031915	44-50
stable	HP:0031915	86-92
anticoagulant	CHEBI:50249	64-77
heparin	CHEBI:28304	122-129
No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)	Eligibility	67
active	PATO:0002354	3-9
condition	PDRO:0000129	35-44
No concurrent combination antiretroviral therapy for HIV-positive patients	Eligibility	68
No concurrent participation in another investigational clinical trial	Eligibility	69
No other concurrent chemotherapeutic agents, endocrine therapy, biologic agents, radiotherapy, or other nonprotocol antitumor therapy	Eligibility	70
radiotherapy	OAE:0000235	81-93
Outcome Measurement:	Results	0
Proportion of Patients With Confirmed Tumor Response	Results	1
Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart.	Results	2
Time frame: Up to 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Treatment (Ziv-afibercept)	Results	5
Arm/Group Description: Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.	Results	6
hour	UO:0000032	60-64
day	UO:0000033	68-71
day	UO:0000033	99-102
disease	DOID:4,OGMS:0000031	122-129
Overall Number of Participants Analyzed: 21	Results	7
Measure Type: Number	Results	8
Unit of Measure: Participants  Confirmed tumor partial response: 1	Results	9
No Confirmed reponse: 20	Results	10
Adverse Events 1:	Adverse Events	0
Total: 10/21 (47.62%)	Adverse Events	1
Left ventricular failure 2/21 (9.52%)	Adverse Events	2
left	HP:0012835	0-4
Sinus tachycardia 1/21 (4.76%)	Adverse Events	3
sinus tachycardia	HP:0011703	0-17
Abdominal pain 1/21 (4.76%)	Adverse Events	4
abdominal pain	HP:0002027	0-14
Disease progression 1/21 (4.76%)	Adverse Events	5
disease	DOID:4,OGMS:0000031	0-7
Platelet count decreased 1/21 (4.76%)	Adverse Events	6
platelet count	CMO:0000029	0-14
Anorexia 1/21 (4.76%)	Adverse Events	7
anorexia	HP:0002039	0-8
Headache 2/21 (9.52%)	Adverse Events	8
headache	HP:0002315	0-8
Ischemia cerebrovascular 1/21 (4.76%)	Adverse Events	9
ischemia	DOID:326	0-8
Proteinuria 1/21 (4.76%)	Adverse Events	10
proteinuria	HP:0000093,DOID:576	0-11
Dyspnea 2/21 (9.52%)	Adverse Events	11
dyspnea	HP:0002094	0-7
Hypertension 2/21 (9.52%)	Adverse Events	12
hypertension	HP:0000822,DOID:10763	0-12
